STOCK TITAN
  1. Home
  2. News
  3. ALNY

Alnylam Pharmaceuticals, Inc. - ALNY STOCK NEWS

Welcome to our dedicated page for Alnylam Pharmaceuticals news (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals stock.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) is at the forefront of RNA interference (RNAi) therapeutics, pioneering a transformative class of medicines aimed at treating and potentially curing a wide range of diseases. Founded in 2002 and based in Cambridge, MA, Alnylam has translated Nobel Prize-winning science into five commercial products: ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), and Leqvio (inclisiran), developed and commercialized in partnership with Novartis. These breakthrough therapeutics address conditions such as hATTR amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, and hypercholesterolemia.

Alnylam is dedicated to expanding its pipeline with several investigational medicines in late-stage development, focusing on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and CNS/ocular diseases. The company’s commitment to sustainable innovation is reflected in its robust product pipeline and strategic collaborations with industry leaders like Roche and Regeneron.

Financially, Alnylam reported robust growth in 2023 with $1.24 billion in global net product revenues, a reflection of its strong commercial execution across its therapeutic products. The company maintains a strong cash position, bolstered by upfront fees from research partnerships and milestone achievements.

Alnylam is also dedicated to corporate responsibility, with initiatives aimed at reducing greenhouse gas emissions, promoting diversity and inclusion in clinical trials, and expanding global health equity through its Alnylam Challengers program. The company’s environmental impact data is third-party verified, underscoring its commitment to transparency and sustainability.

Looking ahead, Alnylam aims to sustain its leadership in RNAi therapeutics with the anticipated release of topline results from the HELIOS-B Phase 3 study and the continued development of promising candidates like zilebesiran for hypertension and mivelsiran for Alzheimer’s disease. For more details on Alnylam’s people, science, and pipeline, visit www.alnylam.com.

News

Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results

Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. (ALNY) will announce its first quarter 2024 financial results on May 2, 2024. The company will discuss its performance and future outlook via a conference call at 8:30 am ET. Participants can register online to access the call and a replay will be available afterward. A live webcast will be accessible on the Investors section of the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
conferences earnings
-
News

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. announces positive results from the KARDIA-2 Phase 2 study evaluating zilebesiran for hypertension treatment. The study showed significant reductions in blood pressure across three independent cohorts, with encouraging safety profiles. Zilebesiran aims to address treatment gaps in hypertension management and offers the potential for biannual dosing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session

Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. will discuss results from the KARDIA-2 Phase 2 study of zilebesiran, an RNAi therapeutic for hypertension, at the ACC Scientific Session. The webcast event will feature presentations and a Q&A session with Alnylam management and Dr. Akshay Desai.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
conferences clinical trial
News

Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease

Rhea-AI Summary
Alnylam Pharmaceuticals Launches Family Health History Road Trip Program to Encourage Health Conversations
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.21%
Tags
none
-
News

ByHeart Appoints Amy Schulman as Chair of the Board of Directors, Further Solidifying its Position as a Leader in the Infant Nutrition Category

Rhea-AI Summary
ByHeart, a next-generation baby nutrition company, appoints Amy Schulman as Chair of the Board, signaling a significant milestone for the company. Schulman, with extensive experience in infant formula and consumer health from Pfizer, brings valuable insights and expertise to ByHeart's leadership team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
management
-
News

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives

Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. announced positive results from the KARDIA-2 Phase 2 study of zilebesiran, an RNAi therapeutic for hypertension. The study met primary endpoints by reducing systolic blood pressure significantly when added to standard antihypertensive treatments. The drug showed promising safety and tolerability profiles, supporting potential biannual dosing. Full study results will be presented at the 2024 American College of Cardiology Annual Scientific Session. Alnylam and Roche also initiated the KARDIA-3 Phase 2 study for patients at high cardiovascular risk with uncontrolled hypertension.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
none
News

Alnylam to Webcast Presentations at Upcoming March Investor Conferences

Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. (ALNY) will be presenting at several upcoming conferences in March 2024 to provide company overviews. The presentations will be webcasted live and available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
conferences
-
News

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity

Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. (ALNY) achieved strong financial results in the fourth quarter and full year of 2023 with $1.24 billion in global net product revenues, marking a 39% annual growth compared to 2022. The company announced positive updates on clinical studies and FDA clearances, setting a combined net product revenue guidance of $1.4-1.5 billion for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.19%
Tags
earnings
-
News

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. (ALNY) will report financial results for Q4 and year ending December 31, 2023, on February 15, 2024. The management will discuss results and future expectations via conference call. Participants can register online and access the call and webcast on the Investors section of the Company’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.75%
Tags
conferences earnings
News

Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association

Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. (ALNY) CEO Yvonne Greenstreet has been named the 2024 Woman of the Year by the Healthcare Businesswomen’s Association (HBA) for her significant contributions to healthcare and the advancement of women in the workplace, announced at the J.P. Morgan Healthcare Conference. The award will be presented on May 10 in New York City. Yvonne has been with Alnylam since 2016 and has held various leadership roles, including Chief Operating Officer, President, Director, and Chief Executive Officer. Under her leadership, Alnylam has been recognized as a socially responsible company and an exceptional workplace. She has made an impact in the biopharmaceutical industry, and her accolades include being named among Fortune’s Best Workplaces for Women and inclusion in the Bloomberg Gender Equality Index.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none

FAQ

What is the current stock price of Alnylam Pharmaceuticals (ALNY)?

The current stock price of Alnylam Pharmaceuticals (ALNY) is $245.44 as of December 20, 2024.

What is the market cap of Alnylam Pharmaceuticals (ALNY)?

The market cap of Alnylam Pharmaceuticals (ALNY) is approximately 30.7B.

What is Alnylam Pharmaceuticals known for?

Alnylam Pharmaceuticals is known for pioneering RNA interference (RNAi) therapeutics, which are innovative medicines designed to silence disease-causing genes.

What products has Alnylam commercialized?

Alnylam has commercialized ONPATTRO (patisiran), AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), and Leqvio (inclisiran).

What diseases do Alnylam’s products treat?

Alnylam’s products treat conditions like hATTR amyloidosis, acute hepatic porphyria, primary hyperoxaluria type 1, and hypercholesterolemia.

What are the recent financial achievements of Alnylam?

In 2023, Alnylam reported $1.24 billion in global net product revenues, reflecting strong commercial execution and growth.

Who are Alnylam’s key strategic partners?

Key strategic partners include Roche, Regeneron, and Novartis, with collaborations focusing on various clinical programs and commercial products.

What environmental initiatives has Alnylam undertaken?

Alnylam has disclosed multiyear data on greenhouse gas emissions, energy, water, and waste management, with third-party verification to ensure transparency and sustainability.

What is the Alnylam Challengers program?

The Alnylam Challengers program is a global health equity initiative that partners with social entrepreneurs and non-profit organizations to address health and economic inequalities.

What are some key pipeline developments for Alnylam?

Key pipeline developments include the HELIOS-B Phase 3 study for vutrisiran in ATTR amyloidosis, and early-stage developments for mivelsiran in Alzheimer’s disease.

Where is Alnylam Pharmaceuticals headquartered?

Alnylam Pharmaceuticals is headquartered in Cambridge, Massachusetts.

How can I learn more about Alnylam Pharmaceuticals?

For more information, visit their official website at www.alnylam.com.

Stock ALNY logo
Alnylam Pharmaceuticals, Inc.

Nasdaq:ALNY

ALNY Rankings

#390 Ranked by Market Cap
N/A Ranked by Dividends

ALNY Stock Data

30.67B
128.18M
0.43%
98.2%
2.9%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE